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This study was undertaken to assess medium-term eﬀects of laparoscopic sleeve gastrectomy (LSG) on body weight and glucose
homeostasisin severelyobesetype 2diabetic (T2DM)subjects. Twenty-ﬁve obeseT2DM subjects (10M/15F,age45±9y ears,BMI
48 ± 8kg/m 2,M± SD) underwent evaluation of anthropometric/clinical parameters and glucose homeostasis before, 3 and 9–15
months after LSG. Mean BMI decreased from 48 ± 8kg/m 2 to 40 ± 9kg/m 2 (P<. 001) at 3 months and 34 ± 6kg/m 2 (P<. 001)
at 9–15 months after surgery. Remission of T2DM (fasting plasma glucose < 126mg/dL and HbA1c < 6.5% in the absence of
hypoglycemic treatment) occurred inallpatientsbut one.Therewasaremarkablereduction inthepercentage ofpatientsrequiring
antihypertensive and hypolipidemic drugs. Our study shows that LSG is eﬀective in producing a signiﬁcant and sustained weight
loss and improving glucose homeostasis in severely obese T2DM patients.
1.Introduction
Obesity is one of the most serious and urgent public
health problems in western societies because of its metabolic
and cardiovascular complications that negatively impact on
life expectancy [1]. Equally alarming is the increase of
morbid obesity (BMI ≥ 40kg/m2) that quadrupled over
the last decade, whereas extreme obesity (BMI > 50kg/m2)
increased ﬁvefold [2].
B a r i a t r i cs u r g e r y ,a l s ok n o w na sm e t a b o l i cs u r g e r y ,h a s
emerged as a highly eﬀective and long-lasting treatment in
patients with morbid obesity and in those with BMI ≥
35kg/m2 i nt h ep r e s e n c eo ft y p e2d i a b e t e s( T 2 D M )a n d
other comorbidities [3]. There is extensive evidence that
bariatric procedures, including biliopancreatic diversion
(BPD), gastric bypass (GBP), and gastric banding, can suc-
cessfully control most of the obesity-related comorbidities,
such as hypertension, dyslipidemia, and T2DM [4]. The rate
of success is higher with the predominantly malabsorptive
and mixed malabsorptive-restrictive procedures than purely
restrictive operations [5].
Laparoscopic sleeve gastrectomy (LSG) is emerging as a
new promising therapy for the treatment of morbid obesity
[6]. This procedure, originally conceived as a ﬁrst stage for
achieving weight loss in superobese patients before perform-
ing GBP or BPD,has revealed to be eﬀectiveon its own and a
potential competitor with these operations. In fact, LSG has
the advantage to be less invasive than GBP and BDP, and not
inferior in terms of sustained weight loss, as demonstrated in
some preliminary studies[6]. Few studieshave examined the
eﬀects of LSG on glucose control and comorbidities in obese
T2DM patients, and limited information is available on the
long-term eﬃcacy of this procedure [7–9]. Therefore, in the
present study we assessed the medium-term (9–15 months)
eﬀects of LSG on body weight and glucose homeostasis in
severelyobeseT2DMsubjectsnotadequatelycontrolledwith2 Journal of Obesity
medicaltherapy. Inaddition,we evaluatedtheimpact ofLSG
on other pathological conditions linked to obesity, that is,
hypertension and dyslipidemia.
2.Methods
The study was conducted at the Department of Surgery, S.
Giovanni Bosco Hospital, Naples and at the Department of
Clinical and Experimental Medicine, Federico II University,
Naples.
A total of 25 obese T2DM subjects (10M/15F, age
45 ± 9y e a r s ,B M I4 8± 8kg/m 2,M± SD) underwent LSG
surgery. All patients were examined by a multidisciplinary
and integrated medical team consisting of a diabetologist, a
bariatric surgeon, a psychiatrist, and a dietician.
The inclusion criteria were as follows: age 35–65 years,
BMI ≥ 35kg/m2, duration of diabetes>1y e a r .E x c l u s i o nc r i -
teria were age <35 years or >65 years, BMI < 35kg/m2,f a s t -
ing C-peptide level <1ng/mL, endocrine obesity, a history
of medical problems such as mental impairment, drug or
alcohol addiction, recent majorv a s c u l a re v e n ta n de x c e s s i v e
surgical risks due to debilitating diseases that considerably
impair life expectancy according to perioperative bariatric
guidelines [9].
All patients underwent complete evaluation before and
at 3 and 9–15 months after surgery including anthro-
pometric/clinical parameters and laboratory tests. Insulin-
resistance was evaluated by the homeostasis model assess-
ment of insulin resistance (HOMA-IR) index using a
standard formula: fasting insulin (U/L) × fasting glucose
(mmol/L) divided by 22.5.
All patients provided written informed consent before
undergoing surgery.
2.1. Operative Technique. All operative procedures were
performed laparoscopically.Theﬁrst stepconsistsinopening
the gastrocolic ligament attached to the stomach, usually
starting 10–12cm from the pylorus toward the lower pole
of the spleen. Then the gastric greater curvature is freed
up to the cardiooesophageal junction close to stomach
sparing the gastroepiploic vessels. Meticulous dissection is
performed at the angle of His with full mobilization of the
gastric fundus. The mobilization of the stomach continues
dissecting the greater gastric curve toward the antrum up to
3–5cmfrom the pylorus. At this time a 40-Frorogastric tube
is inserted direct toward the pylorus, proximal to the lesser
curvature of the stomach. Then, the stomach is resected
with linear staplers parallel to orogastric tube along the
lesser curve starting 3–5cm far from pylorus. The orogastric
bougie is replaced by a nasogastric tube that is positioned
in the distal stomach to perform a methylene blue test. The
transection line is inspected to search blue positivity. In case
of negative test, the resected stomach is removed by left
midabdominal trocar usually without prolonging incision.
The gastric residual volume ranged from 60 to 80mL.
2.1.1. Remission of Comorbidities. Remission of T2DM was
deﬁned as fasting plasma glucose below 126mg/dL and
HbA1c below 6.5% in the absence of hypoglycemic treat-
ment. Remission of hypertension was deﬁned as blood
pressure below 140/90mmHg in the absence of antihyper-
tensive treatment; remission of dyslipidemia was deﬁned
as fasting plasma LDL-cholesterol below 100mg/dL and/or
fasting plasma triglycerides below 190mg/dL in the absence
of pharmacological therapy.
2.2. Statistical Analysis. Results are expressed as mean
± standard deviation or number. ANOVA with repeated
measures was used to detect changes over time of the
anthropometric and biochemical variables. Paired Student’s
t-tests were used to compare data before and after surgery.
A P value of .05 was considered statistically signiﬁcant. All
statistical analyses were performed using SPSS version 13.0
(SPSS Inc., Chicago, IL).
3.Results
The main characteristics of the patients studied are shown
in Table 1. All patients had a duration of T2DM > 1
year (3 ± 2 years), and most of them (68%) were in
poor glycaemic control, as evidenced by HbA1c > 7%.
Two patients were on diet, twenty-one patients took oral
hypoglycemic agents, and two were on combined therapy
(oral agents plus insulin). Twenty-one (84%) patients were
on antihypertensive therapy, and fourteen (56%) patients
received hypolipidemic drugs.
The changes in clinical and biochemical variables follow-
ing LSG are reported in Table 1. Mean BMI decreased from
the basal value of 48 ± 8kg/m 2 to 39 ± 8kg/m 2 (P<. 001)
at 3 months and to 34 ± 6kg/m 2 (P<. 001) 9–15 months
after surgery.Percent excess weight was 81±42%at3months
and 61 ± 33%) at 9–15 months compared to basal value
(122 ± 39%; P<. 001 for both). Fasting plasma glucose
signiﬁcantly decreased to 87 ± 19mg/dL 3 months after LSG
and remained within the normal range at 9–15 months in
all patients but one. Mean HbA1c reached 5.9 ± 0.6% at 3
months and remained unchanged at 9–15 months (5.8 ±
0.7%)(P<. 03).Fastingplasma insulindeclinedsigniﬁcantly
by 68–87% following the intervention (P<. 005). As a
consequenceHOMA-IRdramatically decreased by 86% (P<
.008) 3 months after surgery and remained stable thereafter
(91%, P<. 04).
Following surgery, all patients discontinued their hypo-
glycemic medications, and a full remission of T2DM was
achieved in 24 out of 25 patients. Eighteen patients discon-
tinued antihypertensive drugs, and 12 patients discontinued
hypolipidemic drugs at 3 months. A major perioperative
complication occurred in one patient who was admitted
to intensive care unit for acute renal failure due to severe
dehydration. This complication went to complete resolution
in few days.
4.Discussion
Our study shows that LSG is eﬀective in producing a
signiﬁcant and sustained weight loss and improving glucoseJournal of Obesity 3
Table 1: Changes in body weight, arterial blood pressure, and main biochemical parameters followingLSG.
Baseline
N = 25
3m o n t h s
N = 25
Change
%
P value 9–15 months
N = 15
Change
%
P value
Body weight (Kg) 136 ±30 112 ±30 18 .001 98 ±25 28 .001
BMI (Kg/m2) 48 ±83 9 ±81 9 .001 34 ± 63 0 .001
FPG (mg/dL) 131 ±42 87 ±19 33 .008 91 ±20 31 .01
FPI (mU/L) 20 ±13 6.5 ±56 8.005 2.5 ±0.78 7 .001
HbA1c (%) 7.5 ±1.95 .9 ±0.62 1 .03 5.8 ±0.72 3.03
HOMA-IR 6.4 ±3.90 .7 ± 0.35 86 .008 0.54 ± 0.29 1.04
Total cholesterol (mg/dL) 201 ±42 199 ±46 1 ns 228 ± 51 12 ns
LDL-cholesterol (mg/dL) 121 ±29 120 ±37 1 ns 146 ± 40 17 ns
Triglycerides (mg/dL) 198 ±123 119 ±42 40 .04 104 ± 17 47 ns
SBP (mmHg) 124 ±8 118 ±11 5 ns 126 ± 12 2 ns
DBP (mmHg) 77 ±96 8 ±11 12 ns 79 ± 93 ns
Hypoglicemic drugs (n) 23 0 0
Anti-hypertensive drugs (n) 21 3 2
Hypolipidemic drugs (n) 14 2 2
homeostasis in severely obese T2DM patients. In fact, after
9–15 months from surgery all patients but one achieved
a good glycemic control with discontinuation of hypogly-
caemic treatment. This ﬁnding is in line with previous
studies demonstrating that diabetes resolution occurs in 66–
80% of patients undergoing LSG [7–11].
Although the mechanisms underlying T2DM remission
following LSG has yet to be fully determined, some human
studies have reported favourable changes in insulin sen-
sitivity [12, 13]. In our patients, insulin resistance eval-
uated by HOMA index decreased by 80% thus conﬁrm-
ing previous data by Abbatini et al. who demonstrated
a near-normalization of insulin resistance measured by
euglycemic clamp in patients treated with LSG [12]. The
improvement in insulin sensitivity is primarily due to weight
loss, reduction in inﬂammatory mediators, and decreased
calorie intake although the contribution of weight indepen-
dent mechanisms seems very likely. Potential mechanisms
include enhanced stimulation of gastrointestinal hormones
secondary to rearrangement of gastrointestinal anatomy.
For malabsorptive/mixed procedures (RYGB and BDP)
relevant and rapid changes in the enterohormonal axis
have been demonstrated, consisting of complete recovery
of meal-stimulated response of GLP-1 and GIP [14]. These
modiﬁcations, evident already a few days after surgery,
may explain the rapid improvement of glucose homeostasis
before substantial weight loss has occurred [14, 15]. The
long-term evaluation of these patients has also shown
that the recovery of incretin response is maintained over
time, probably contributing to the recovery of beta-cell
function [16]. Regarding LSG, recent studies have shown
that this procedure is associated with a marked reduction
of ghrelin secretion, an orexigenic peptide produced by the
gastric fundus involved in mealtime hunger regulation [17].
Ghrelin is also known to exert several diabetogenic eﬀects
(increase in growth hormone, cortisol, and epinephrine);
therefore its suppression could contribute to improved
glucose homeostasis. Interestingly, we observed an increased
meal-stimulated GLP-1 and GIP response in our patients at
3 weeks postoperatively, which may have concurred to ame-
lioration of glucosemetabolism (unpublished observations).
None of the patients studied presented any sign of nutri-
tional deﬁcienciesat9–15-month follow-up, conﬁrming that
LSG is a safe procedure in terms of nutritional status at odds
withmalabsorptiveormixedsurgicalprocedureswhichoften
lead to multiple nutritional consequences due to the bypass
of duodenum and jejunum [18].
In conclusion, LSG induces stable weight loss and
resolution of T2DM diabetes and other obesity-associated
comorbidities in a large majority of patients. Controlled
long-term comparisons between diﬀerent bariatric inter-
ventions are needed to establish the optimal procedure in
relation to patients’ characteristics.
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